Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group
Recommended Citation
Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, and Wen PY. Brain malignancy steering committee clinical trials planning workshop: Report from the targeted therapies working group. Neuro Oncol 2015; 17(2):180-188.
Document Type
Article
Publication Date
2-1-2015
Publication Title
Neuro Oncol
Abstract
Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.
Medical Subject Headings
Biomarkers; Brain Neoplasms; Clinical Trials as Topic; Endpoint Determination; Glioblastoma; Humans
PubMed ID
25165194
Volume
17
Issue
2
First Page
180
Last Page
188
